Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Envarsus vs Advagraf in Liver Transplant
NCT03241043Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- May 2016
- Primary completion
- Apr 2019
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in Liver transplant rejection (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Average Cumulative Dose (DAV) at 20 months, Trough Level at Steady State / Daily Dose at Steady State at 20 months and 1 more. Started May 2016; status: completed.
02
Drugs
tacrolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT03241043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241043.